Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

New product aims to prevent DVT and PE

New product aims to prevent DVT and PE

Publication date: Thursday, 07 February 2019

A new simple device has been designed to improve venous blood flow of people when seated and to help in the prevention, care and treatment of deep vein thrombosis and pulmonary embolism.

The RBR legflow™ was created with the input of Professor Richard Beasley, director of the Medical Research Institute of New Zealand (MRINZ) and a world authority on respiratory medicine who has undertaken ground-breaking research of ‘e-thrombosis’.

He said: “Research from the MRINZ has shown that this device markedly increases lower limb venous blood flow, thereby potentially reducing the risk of blood clots, in people who sit for long periods at work or with long distance air travel.”

As part of its design, the RBR legflow™ is manufactured with an antimicrobial ingredient which offers excellent protection against bacteria, biofilm, fungi and mould, and has no adverse effect on the RBR legflow™ properties. This antimicrobial element remains effective for the lifetime of the product and all the active components used are approved by the FDA and EPA. The aim is to dramatically reduce the risk of any cross-infection.

Thrombosis key facts:

  • The cost of thrombosis to the NHS is estimated at over £200 million a year.
  • Globally this is a cost to health service providers of more than £22 billion each year.
  • More than 60% of all cases of VTE are associated with hospitalisation, with many events occurring up to 90 days after admission.
  • VTE affects approximately one in 1000 of the UK population and is a significant cause of mortality, long-term disability and chronic ill-health problems.
  • In Europe, there are 544,000 VTE-related deaths every year.
  • In the US and Europe, VTE-related events kill more people than AIDS, breast cancer, prostate cancer and motor vehicle crashes combined
  • In the UK, up to 60% of VTE cases occur during or after hospitalisation, making it the leading preventable cause of hospital death
  • Hospital-acquired blood clots cause an estimated 25,000 preventable deaths each year


More information

For more details on this product visit the RBR Active website at https://www.rbractive.com/



CVD prevention opportunities here and now

Updated NICE guidance will help people in hospital most at risk of VTE

BACK TO BASICS: Oral drug targets in type 2 diabetes

Topics covered:
Category: Have You Heard
Edition: Volume 4, Number 2, BJPCN Online 2019

Article search and filter